Laboratory monitoring of new anticoagulants

American Journal of Hematology

Volumn 85, Issue 3, 2010, Pages 185-187

  Castellone, Donna D ^a   Van Cott, Elizabeth M ^b  

^a Siemens Healthcare Diagnostics Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; ECARIN; FONDAPARINUX; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; RIVAROXABAN; THROMBIN; WARFARIN;

ANALYTIC METHOD; ARTICLE; BLEEDING TIME; DRUG MONITORING; FIBRINOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBOCYTE FUNCTION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR XA; HUMANS; PIPECOLIC ACIDS; THROMBIN; WARFARIN;

EID: 77249146517     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21607     Document Type: Article

References (17)

1. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004;30:683-695.
2. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38:99-109.
3. Walenga J. Direct Thrombin Inhibitors and Laboratory Monitoring Issues. Coagulation Symposium, Indianapolis, 2006.
4. Shaikh S, Van Cott EM. The effect of argatroban on activated protein C resistance. Am J Clin Pathol 2009;131:828-833.
5. Gosselin RC, King JH, Janatpour KA, et al. Comparing direct thrombin inhibitors using APTT, ECT and thrombin inhibitor management testing. Ann Pharmacother 2004;38:1383-1388.
6. Castellone DD, Peerschke EIB. A Chromogenic Method for Quantitation of Direct Thrombin Inhibitors: A Case Study (Abstract). Geneva: International Society on Thrombosis and Haemostasis (ISTH); 2006.
7. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003/2004;33:173-183.
8. Smogorzweska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays. Arch Pathol Lab Med 2006;130:1605-1611.
9. Gosselin RC, King JH, Janatpur KA, et al. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004;128:1142-1145.
10. GlaxoSmithKline (GSK) Package Insert, Arixtra (Fondaparinux Sodium) Injection. Research Triangle Park, NC: GlaxoSmithKline (GSK); 2004.
11. Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT dose-ranging study. Blood 2008;112:2242-2247.
12. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.
13. Calatzis A, Dirk Peetz D, Haas S, et al. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008;130:446-454.
14. Pentapharm. Package Insert, Pefakit PiTC Assay. Basel, Switzerland: Pentapharm; 2008.
15. Varadi L, Turecek PL, Schwarz P. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004;10:17-21.
16. Arpino P, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005;25:157-164.
17. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-185.